RCS - Oxford BioDynamics - OBD develops multi-cancer diagnostic test for dogs

Oxford BiodynamicsAnnouncement

04/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240604:nRSD9448Qa&default-theme=true

RNS Number : 9448Q  Oxford BioDynamics PLC  04 June 2024

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

OBD

Oxford BioDynamics develops a high accuracy,

discriminating diagnostic test for multiple canine cancers

·    EpiSwitch® Specific Canine Blood (EpiSwitch® SCB) test is a new
canine multi-cancer diagnostic test based on OBD's non-invasive EpiSwitch®
array platform

·    Test developed in collaboration with leading US KOL Professor Jaime F
Modiano, University of Minnesota, USA

·    Test offers early blood-based detection and discrimination of six
high-utility, frequently occuring cancer types: three sarcomas, two lymphomas,
and malignant melanoma, each with balanced accuracy of >89%

·    Real-world utility data with selected veterinary services will
further validate the test

Oxford, UK - 4 June 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a
biotechnology company developing precision medicine tests based on the
EpiSwitch® 3D genomics platform, announces development of a high-accuracy,
discriminating multi-cancer canine diagnostic test for veterinary medicine.

The test was developed in collaboration with Veterinary Referral Associates,
Gaithersburg MD, USA; Animal Cancer Care and Research Program, University of
Minnesota, St. Paul, MN, USA; Department of Veterinary Clinical Sciences,
College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA;
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Center
for Immunology, University of Minnesota, Minneapolis, MN; Stem Cell Institute,
University of Minnesota, Minneapolis, MN; Department of Laboratory Medicine
and Pathology, University of Minnesota Medical School, Minneapolis, MN; and
Institute for Engineering in Medicine, University of Minnesota, Minneapolis,
MN.

OBD's EpiSwitch® SCB ("Scooby") test is a well balanced, highly accurate
blood test to specifically diagnose canine diffuse large B-cell lymphoma
(DLBCL), T-zone lymphoma (TZL), hemangiosarcoma (HSA), histiocytic sarcoma,
osteosarcoma, and canine malignant melanoma, in a powerful single assay
format. The test was validated using 3D whole-genome profiling in peripheral
blood. It demonstrated high sensitivity and specificity for lymphomas and
sarcomas as a class (accuracy >80%); and high sensitivity and specificity
for specific individual indications, with an accuracy >89%. The validation
results are published in BioRxiv (link here
(https://url.avanan.click/v2/___https:/www.biorxiv.org/content/10.1101/2024.05.22.595358v1___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpkOGM0OmYyYzM0MzExZDEzMzlmNTc0MDU1M2JjNzA5MWE3ZmJhZjdkNjgzOWZhYjVlZDNlMmFiYzFkN2I0OTliOWVkM2I6cDpU)
).

There is a critical need in veterinary oncology for an accurate, specific,
sensitive, non-invasive (blood) biomarker assay to assess canine oncological
indications earlier, to better inform therapeutic interventions. Current
alternatives for non-invasive canine cancer detection deliver only a
"cancer/no cancer" outcome, with low specificity and no distinction between
different cancer types. Effective therapeutic intervention requires a
definitive identification of a specific cancer type - often a difficult task
in current veterinary practice.

OBD's newly published study demonstrates a novel 3D genomic approach that can
diagnose six canine cancers, as well as support continuing upgrade for
additional diagnostic profiles, in a  modular manner. The EpiSwitch® SCB
test promises to help veterinary specialists to diagnose the disease, make
more informed treatment decisions, minimize or avoid unnecessarily toxicity,
and efficiently manage costs and resources.

EpiSwitch SCB will be made available to a select group of vets who will
generate real-world utility data that will further validate the test. It is
expected that the commercialisation of the EpiSwitch ECB test will be through
a partnership or outlicensing arrangement with an organisation with an
existing presence in the pet healthcare market.

Dr Sara Fritz, Veterinary Referral Associates, Gaithersburg MD, USA, said: "My
first use of the EpiSwitch SCB test helped navigate a very complex case of
canine cancer relapse in the absence of options from the current standards of
care. This test opens possibilities for a quick and reliable diagnosis in the
very cases where time is at premium."

Professor Jaime Modiano, College of Veterinary Medicine and Masonic Canecr
Cemnter, University fo Minnesota, USA said: "The ability to detect the
presence of common, life-threatening dog cancers with high accuracy using
blood samples provides an improvement over current methods of diagnosis,
reducing or eliminating the need for invasive biopsy procedures. I believe
that the eventual implementation of these tests also has potential to enhance
the precision and therefore improve the management and outcomes of canine
cancer patients."

Dr Alexandre Akoulitchev, CSO, OBD said: "EpiSwitch SCB combines all the
advantages of EpiSwitch blood based biomarkers with a novel proprietary
multi-choice EpiSwitch array design. Once again, we were determined to
translate to practice the full potential of our EpiSwitch technology, this
time to tackle a prevalent veterinary challenge in support of our four legged
friends."

Reference

Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Tarun Naithani, Dominik
Vugrinec, Kyrylo Shliaiev, Mutaz Issa, Cicely Weston, Abigail Hatton, Abel
Gebregzabhar, Jane Green, Anthony Blum, Thomas Guiel, Sara Fritz, Davis
Seelig, Jaime F Modiano, Alexandre Akoulitchev

bioRxiv 2024.05.22.595358; doi: https://doi.org/10.1101/2024.05.22.595358
(https://url.avanan.click/v2/___https:/doi.org/10.1101/2024.05.22.595358___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjOTQzOmI1ZjVkOWI4NTBjMzkxNjY4ZjZjYmU0YWNlMzRkZjIzMWZlZTU0YTBhNjNjYjYwZjEwODE0NzRhZTdkNTcwNzI6cDpU)

Whole Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and
Validation of EpiSwitch Multi-Choice Array-Based Diagnostic Test.

 

- Ends -

For further details please contact:

 Oxford BioDynamics Plc                  +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                           +44 (0)20 7408 4090

(Nominated Adviser and Broker to OBD)

 Stephane Auton

 Lucy Bowden

 WG Partners                             +44 (0)20 3705 9330

 (Joint Broker to OBD)

 David Wilson / Claes Spång /

Sateesh Nadarajah / Erland Sternby

 Instinctif Partners                     Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
 (Media / Analyst enquiries for OBD)

Melanie Toyne-Sewell / Katie Duffell

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

It has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE is a blood test that
boosts the predictive accuracy of a PSA test from 55% to 94% when testing the
presence or absence of prostate cancer, launched in the US and UK in
September 2023. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in February
2022.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring, in a wide range of
indications, including oncology, neurology, inflammation, hepatology and
animal health.

In March 2021, the Company launched the first commercially available
microarray kit for high-resolution 3D genome profiling and biomarker
discovery, EpiSwitch® Explorer Array Kit
(https://url.avanan.click/v2/___http:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo0ZTU1OjIxYzYwYjMwMmY3Yzg3MzhlMTllY2IyNTRlYWQzMzk5ZWZmMzM2NjMyZTQyYmQwZmEyZDgwY2U0Yjg4M2JkOWU6cDpU)
, which is available for purchase by the life science research community.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD's group headquarters and research, product development and UK clinical
laboratories are in Oxford, UK. It also has a commercial office
in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a
reference laboratory in Penang, Malaysia.

The company is listed on the London Stock Exchange's AIM, with ticker OBD. For
more information, please visit the Company's
website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/x.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjplZWUzOjc5NjFkZGM3Y2Y0ZDI5N2UxMmRlMWViM2UyODQwODYwZWNmMjNiMTM1NTMzMDQ1NDlhYmI3YTMwYjFlNTI3ZDk6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUAWQUPCGBW